Company intelligence / Profile preview

Mesa Biotech

San Diego, California, United States

Ownership: Public · MLAB
Employees: ~30
Development stage: Commercial

Overview

Mesa Biotech developed the Accula System, a rapid point-of-care PCR platform for infectious disease diagnosis. The system delivers results in about 30 minutes and has received FDA Emergency Use Authorization for SARS-CoV‑2 testing as well as 510(k) clearance and CLIA waiver for Flu A/B, RSV, and Strep A tests. The company was acquired by Thermo Fisher Scientific in February 2021[6][1].

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic assay (PCR-based)
Industry: Molecular Diagnostics

Partnerships

Biomedical Advanced Research and Development AuthorityNational Institutes of Health

Financials

Market cap: $692.4M
Total revenue: $60.1M
Enterprise value: $763.1M

Beyond the preview

Go deeper on Mesa Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesa Biotech.

Explore the full profile